



METHODOLOGY CONTACT US VENABLE LLP

BIOLOGICSHQ SEARCH NEWS STATISTICS BIOLOGICSHQ TEAM RESOURCES SUBSCRIBE

Statistics at a Glance



Biosimilar-Related IPR Petitions



165* IPRs

*Considering IPR2017-00826 and IPR2017-01008 as one IPR, and IPR2017-00827 and IPR2017-01009 as one IPR.



As of Jun. 15, 2025

CONCERNING:



77 Patents

CONCERNING:



16* CDER-Listed Reference Products

*Considering Epogen/Procrit as a single product. Includes Insulin.

© Venable LLP 2025. All Rights Reserved.

Biosimilar-Related IPR Petitions include IPR petitions relating to biosimilar/follow-on products. IPR petitions relating to disputes between reference product sponsors, or non-practicing entities/universities and reference product sponsors are not included. IPR petitions relating to manufacturing patents that may be relevant to multiple products (for example, U.S. Patent No. 6,331,415 (a "Cabilly" patent)) also are not included.

BiologicsHQ and materials published on BiologicsHQ are published for informational purposes only. Neither the information nor any opinion expressed on BiologicsHQ constitute legal advice, create an attorney-client relationship, or constitute a solicitation for business.

SHARE



ATTORNEY ADVERTISING

© TM / © Venable LLP 2025. All Rights Reserved.

Related Websites

VENABLE.COM →

DISCLAIMER →

Amgen Exhibit 1083
Amgen v. BMS
IPR2025-00601